Statins, drugs widely prescribed to lower cholesterol, do not interfere with a commonly used medication to treat lymphomas, according to a Mayo Clinic study presented at the 50th Annual Meeting of the American Society of Hematology in San Francisco. In fact, statins may slow the progression of certain types of lymphoma. The study focused on
Full Post: Statins do not interfere with Rituximab treatment for lymphomas
Experiments at Johns Hopkins have found that the gradual maturing of embryonic cells into cells as varied as brain, liver and immune system cells is apparently due to the shut off of several genes at once rather than in individual smatterings as previous studies have implied.
Working with mouse brain and liver cells, as well as embryonic stem cells, Johns Hopkins University School of Medicine professor Andrew Feinberg, M.D., M.P.H., led an investigation of a kind of epigenetic modification to histones, the molecular “spools” that DNA winds around in the cell nucleus. This modification is a variety of the so-called epigenetic changes that alter the function of cells without directly altering the nuclear DNA in the cells.
Other scientists had previously found that histone modifications appear to silence individual genes in the DNA that coils around affected histones. But when Feinberg and his team compared the activity of thousands of genes in the liver and brain cells, they found that a particular modification - in which two methyl groups clip onto histones - seemed to silence long stretches of DNA containing many genes at once. The findings will publish in Nature Genetics online on Jan. 18.
Since the silenced stretches varied greatly between the different types of cells, Feinberg, postdoctoral fellow Bo Wen, and their colleagues wondered whether these sections - called large organized chromatin K9 modifications, or LOCKS - might be responsible for the transition from the “blank slate” quality of embryonic cells to the specialized functions that mature cells take on. To find out, he and his team looked for LOCKs in mouse embryonic stem cells. Unlike mature, adult liver and brain cells, in which about 40 percent of the genome was silenced by LOCKs, the embryonic stem cells had no LOCKs.
Next, the researchers compared the regions of DNA affected by LOCKs between mouse liver and brain cells and their corresponding human cells. The same cell types in both organisms had remarkably similar regions of DNA silenced by LOCKs, suggesting that the same genes necessary to control cell function are affected in mice and people.
“These results suggest that LOCKs appear gradually during development, refining cells’ functions as they differentiate into particular cell types,” Wen says. “Our experiments suggest that the whole forest of genes is changing, but people have been looking at the individual trees.”
Because epigenetic changes also are known to play a role in abnormal cell growth, the researchers suspected that LOCKs were involved in the development of cancer. When they looked for genes in several common cancer cell lines often used in research, they indeed found significantly fewer LOCKs than in normal liver and brain cells.
“In cancer, some of these LOCKs may become unlocked,” says Feinberg. “Sections of DNA that were silenced in a cell type might become active, giving cancer cells characteristics of other cell types that they’re not supposed to have.”
Feinberg says this “unlocking” might cause cancer cells to revert to a more immature developmental state, explaining some of their unusual behavior, such as extreme proliferation or migration to different areas of the body.
http://www.hopkinsmedicine.org/
--------------------------------------------------------------------------------------------
Related Posts:
The study, which appears in the December 18 online version of Cell Stem Cell and the January 2009 print edition of the journal, provides proof of principle that alternative sources of stem cells can be created. The team, which included scientists from Scripps Research, Peking University, and the University of California, San Diego, conducted the
Full Post: Scientists develop method for generating novel stem cells
A very difficult-to-treat child leukemia may benefit from the discovery of a small but potent epigenetic change that launches the cancer - but could potentially be reversed relatively easily, preventing cancer-promoting genes from being turned on. The study, led by researchers at Children’s Hospital Boston and the Dana-Farber Cancer Institute, is the cover article in the
Full Post: Targeting epigenetic changes helps tackle MLL-AF4 leukemias
Scientists at the Stanford University School of Medicine and at UC-San Francisco have succeeded in isolating stem cells from human testes. The cells bear a striking resemblance to embryonic stem cells - they can differentiate into each of the three main types of tissues of the body - but the researchers caution against viewing them
Full Post: Stem cells from human testes can change into other body tissues
Researchers have identified a stage during dopamine neuron differentiation that may be an ideal time to collect human embryonic stem cells for transplantation to treat Parkinson’s disease, according to data presented at Neuroscience 2008, the 38th annual meeting of the Society for Neuroscience. Lorraine Iacovitti, Ph.D., professor and interim director of the Farber Institute for
Full Post: Researchers identify best time for stem cell collection for Parkinson’s therapy
Stem cell researchers at UCLA have proven definitively that blood stem cells are made during mid-gestational embryonic development by endothelial cells, the cells that line the inside of blood vessels. While the anatomic location in the embryo where blood stem cells originate has been well documented, the cell type from which they spring was less
Full Post: Scientists show that endothelial cells give rise to blood stem cells --------------------------------------------------------------------------------------------
